Agile Therapeutics, Inc. AGRX
Set alert
1.51 0.00 0.00%
As of Aug 22, 3:58 PM ET
1.44 Day range 1.51
52-week range unavailable
- Open
- 1.48
- Prev close
- 1.51
- Mkt cap
- 889.10K
- Vol
- 119.29K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.44
- High
- 1.51
- Forward P/E
- 0.27
- Beta
- 1.50
- Short ratio
- 0.28
- Inst. own
- 10.13%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 0.91428
- 200-d avg
- 1.89
- 1y target
- 5.00
2Y chart
Events in this range
- Apr 11, 2023Split: 1 for 50
- May 11, 2023Earnings: —; estimate 0; surprise —%
- Jun 6, 2023Rating: HC Wainwright & Co. · Buy → Buy
- Aug 9, 2023Earnings: —; estimate -3.48; surprise —%
- Sep 21, 2023Rating: Maxim Group · Hold → Buy
- Nov 9, 2023Earnings: —; estimate 0; surprise —%
- Mar 28, 2024Earnings: —; estimate 0; surprise —%
- May 15, 2024Earnings: —; estimate 0; surprise —%
- Aug 12, 2024Earnings: —; estimate 0; surprise —%
Signals (57)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Jul 17, 2024 | 2 years ago |
| SMA: Bullish | Jun 26, 2024 | 2 years ago |
| SMA: Bullish | Jun 26, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 26, 2024 | 2 years ago |
| RSI: Overbought | Jun 26, 2024 | 2 years ago |
| RSI: Oversold | Jun 21, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 18, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 5, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 27, 2024 | 2 years ago |
| RSI: Oversold | Mar 26, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 20, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 15, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 6, 2024 | 2 years ago |
| RSI: Oversold | Feb 20, 2024 | 2 years ago |
| RSI: Oversold | Feb 9, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 7, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 26, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 18, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 12, 2024 | 2 years ago |
| MACD: Sell Signal | Dec 12, 2023 | 2 years ago |
| SMA: Bullish | Nov 15, 2023 | 2 years ago |
| SMA: Bearish | Nov 13, 2023 | 2 years ago |
| SMA: Bullish | Nov 9, 2023 | 2 years ago |
| SMA: Bearish | Nov 6, 2023 | 2 years ago |
| SMA: Bullish | Nov 2, 2023 | 2 years ago |
| MACD: Buy Signal | Oct 20, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 9, 2023 | 3 years ago |
| SMA: Bearish | Oct 3, 2023 | 3 years ago |
| SMA: Bullish | Sep 29, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 27, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 15, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 24, 2023 | 3 years ago |
| RSI: Oversold | Aug 24, 2023 | 3 years ago |
| RSI: Oversold | Aug 10, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 9, 2023 | 3 years ago |
| MACD: Buy Signal | May 24, 2023 | 3 years ago |
| MACD: Sell Signal | May 16, 2023 | 3 years ago |
| RSI: Oversold | May 10, 2023 | 3 years ago |
| MACD: Buy Signal | May 3, 2023 | 3 years ago |
| RSI: Oversold | Apr 26, 2023 | 3 years ago |
| RSI: Oversold | Apr 14, 2023 | 3 years ago |
| RSI: Oversold | Apr 11, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 10, 2023 | 3 years ago |
| SMA: Bearish | Mar 23, 2023 | 3 years ago |
| SMA: Bullish | Mar 22, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 21, 2023 | 3 years ago |
| SMA: Bearish | Feb 23, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 27, 2023 | 3 years ago |
| RSI: Overbought | Jan 5, 2023 | 3 years ago |
| SMA: Bullish | Jan 4, 2023 | 3 years ago |
| SMA: Bearish | Jan 3, 2023 | 3 years ago |
| SMA: Bullish | Dec 30, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 30, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 10, 2022 | 3 years ago |
| SMA: Bearish | Nov 8, 2022 | 3 years ago |
| RSI: Oversold | Oct 7, 2022 | 4 years ago |
| RSI: Oversold | Sep 21, 2022 | 4 years ago |
Key statistics
- Market cap
- 889.10K
- Enterprise value
- 573.31K
- Trailing P/E
- 0.04
- Forward P/E
- 0.27
- PEG ratio
- 0.00
- Price / sales
- 0.04
- Price / book
- 0.00
- EPS (TTM)
- 7.31
- Beta
- 1.50
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -69.72%
- Revenue (TTM)
- 19.98M
- Revenue growth
- 121.90%
- Free cash flow
- -4.36M
- Total cash
- 2.87M
- Total debt
- 2.52M
- Return on equity
- 0.00%
- Shares outstanding
- 2.96M
- Short % of float
- 7.50%
- 50-day average
- 0.91428
- 200-day average
- 1.89
Analyst view
Consensus: hold
Hold
Price target (mean) 5.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.51.
Financials — quick view
AGRX Revenue — quarterly 3.61M
AGRX Net income — quarterly -4.47M
AGRX EPS — quarterly -1.41
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 9, 2023 | Jun 1, 2023 | -3.48 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 21, 2023 | Maxim Group | up | Hold | Buy |
| Jun 25, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 6, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Agile Therapeutics, Inc.
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.
- Country
- United States
- Website
- agiletherapeutics.com
News
- Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.
- Agile Leadership for Pharma and Biopharma Professionals in a Hybrid World: 2-Day Training Course (Online) November 18-19, 2024 - Become Competent and Familiar in a Range of Well-Recognised Leadership Techniques
- STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Agile Therapeutics, Inc. - AGRX
- AGRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Agile Therapeutics, Inc. Is Fair to Shareholders
- Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
- Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript
- Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
- Agile Therapeutics Announces Delisting from Nasdaq
- Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
Your note
Sign in to keep a note on AGRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTOMARI ALFRED | Chief Executive Officer | Stock Award(Grant) | Jun 27, 2023 | 47,749 |
| BARBARI SHARON SURREY A | Director | Stock Award(Grant) | Jun 7, 2023 | 974 |
| CARSON SANDRA | Director | Stock Award(Grant) | Jun 7, 2023 | 974 |
| COIANTE SCOTT M | Chief Financial Officer | Stock Award(Grant) | Oct 2, 2023 | 20,080 |
| CONWAY ROBERT G. | Officer | Stock Award(Grant) | Jun 27, 2023 | 13,529 |
| FISCHER SETH H Z | Director | Stock Award(Grant) | Jun 7, 2023 | 976 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 6.33% | 122,000 | 359.90K | Jun 29, 2023 |
| State Street Corporation | 0.56% | 10,843 | 31.99K | Jun 29, 2023 |
| Blackrock Inc. | 0.31% | 6,061 | 17.88K | Jun 29, 2023 |
| Tower Research Capital LLC (TRC) | 0.14% | 2,712 | 8.00K | Jun 29, 2023 |
| Investor AB | 0.09% | 1,754 | 5.17K | Jun 29, 2023 |
| Royal Bank of Canada | 0.04% | 758 | 2.24K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.21% | 4,098 | 15.53K | May 30, 2023 |
| Vanguard Extended Market Index Fund | 0.20% | 3,765 | 11.11K | Jun 29, 2023 |
| Fidelity Series Total Market Index Fund | 0.03% | 502 | 1.90K | May 30, 2023 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.02% | 295 | 767 | Aug 30, 2023 |